Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 2, 2010, Pages 154-161

  Harries, Katie ^a   Zachariah, Rony ^a   Manzi, Marcel ^a   Firmenich, Peter ^b   Mathela, Richard ^a   Drabo, Joseph ^c   Onadja, G ^d   Arnould, Line ^b   Harries, Anthony ^e,f  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

^c Service d'Urologie   (Burkina Faso)

^d Ministerial Coordination Committee on HIV/AIDS ^*  (Burkina Faso)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral therapy; Burkina Faso; HIV 1; HIV 2; Treatment outcome; Treatment response

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PATIENT COMPLIANCE; SEROTYPE; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; URBAN AREA;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-HIV AGENTS; BODY WEIGHT; BURKINA FASO; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; SEX DISTRIBUTION; SURVIVAL ANALYSIS; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 75449118497     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2009.08.012     Document Type: Article

References (41)

1. Kanki P.J., Travers K.U., Mboup S., Hsieh C.C., Marlink R.G., Guèye-Ndiaye A., et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343 (1994) 943-946
2. Horsburg C.R., and Holmbreg S.D. The global distribution of human immunodeficiency virus type 2 (HIV-2) infection. Transfusion 28 (1988) 192-195
3. Marlink R.G., Ricard D., Mboup S., Kanki P.J., Romet-Lemonne J.L., N'Doyio I., et al. Clinical, hematologic and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type 2. AIDS Res Hum Retroviruses 2 (1988) 137-148
4. Marlink R. Lessons from the second virus, HIV-2. AIDS 10 (1996) 689-699
5. Whittle H., Morris J., Todd J., Corrah T., Sabally S., Bangali J., et al. HIV-2-infected patients survive longer than HIV-1 infected patients. AIDS 8 (1994) 1617-1620
6. Marlink R., Kanki P., Thior I., Travers K., Eisen G., Siby T., et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265 (1994) 1587-1590
7. Loussert-Ajaka I., Simon F., Farfara I., Descamps D., Collin G., and Brun-Vézinet F. Detection of circulating human immunodeficiency virus type 2 in plasma by reverse transcription polymerase chain reaction. Res Virol 146 (1995) 409-414
8. Jaffar S., Wilkins A., Ngom P.T., Sabally S., Corrah T., Bangali J.E., et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. Acquir Immune Defic Syndr Hum Retrovirol 16 (1997) 327-332
9. Pouslen A.G., Aaby P., Gottschau A., Kvinesdal B.B., Dias F., Mølbak K., et al. HIV-2 infection in Bissau, West Africa, 1987-9: incidence, prevalence and routes of transmission. J Acquir Immune Defic Syndr 6 (1993) 941-948
10. Norrgren H., Marquina S., Leitner T., Aaby P., Melbye M., Poulsen A.G., et al. HIV-2 genetic variation and DNA load in asymptomatic carriers and AIDS cases in Guinea-Bissau. J Acquir Immune Defic Syndr Hum Retrovirol 16 (1997) 31-38
11. Schim van der Loeff M., Jaffar S., Aveika A., Sabally S., Corrah T., Harding E., et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in the Gambia. AIDS 16 (2002) 1775-1783
12. Norrgren H., Andersson S., Biague A.J., Dias F., Naucler A., and Biberfeld G. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection. AIDS 13 (1999) 701-707
13. Weidle P.J., Malamba S., Mwebaze R., Sozi C., Rukundo G., Downing R., et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival and drug resistance. Lancet 360 (2002) 34-40
14. Wester C.W., Kim S., Bussmann H., Avalos A., Ndwapi N., Peter T.F., et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40 (2005) 336-343
15. Coetzee D., Hildebrand K., Boulle A., Maartens G., Louis F., Labatala V., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18 (2004) 887-895
16. Stringer J.S., Zulu I., Levy J., Stringer E.M., Mwango A., Chi B.H., et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia - feasibility and early outcomes. JAMA 296 (2006) 782-793
17. Lawn S.D., Myer L., Harling G., Orrell C., Bekker L.G., and Wood R. Determinants of mortality and non-death losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43 (2006) 770-776
18. Calmy A., Pinoges L., and Szumilin E. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20 (2006) 1163-1169
19. Ferradini L., Jeannin A., Pinoges L., Izopet J., Odhiambo D., Mankhambo L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367 (2006) 1335-1342
20. Etard J.F., Ndiaye I., Thierry-Mieg M., Guèye N.F., Guèye P.M., Lanièce I., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20 (2006) 1181-1189
21. Ndour C.T., Batista G., Manga N.M., Ngom Guèye N.F., Dia Badiane N.M., Fortez L., et al. Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study. Med Mal Infect 36 (2006) 111-114
22. Toure S., Kouadio B., Seyler C., Traore M., Dakoury-Dogbo N., Duvignac J., et al. Rapid scaling-up of antiretroviral therapy in 10 000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS 22 (2008) 873-882
23. Andersson S., Norrgren H., da Silva Z., Biague A., Bamba S., Kwok S., et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa. Arch Intern Med 160 (2000) 3286-3293
24. Adjorlolo-Johnson G., Decock K.M., Ekpini E., Vetter K.M., Sibailly T., Brattegaard K., et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 272 (1994) 462-466
25. Andreasson P.A., Dias F., Naucler A., Andersson S., and Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 7 (1993) 989-993
26. Morgan G., Wilkins H.A., Pepin J., Jobe O., Brewster D., Whittle H., et al. AIDS following mother-to-child transmission of HIV-2. AIDS 4 (1990) 879-882
27. Matheron S., Courpotin C., Simon F., Di Maria H., Balloul H., Bartzack S., et al. Vertical transmission of HIV-2. Lancet 335 (1990) 1103-1104
28. De Cock K., Zadi F., Adjorolo G., Diallo M., Sassan-Morokro M., Ekpini E., et al. Retrospective study of maternal HIV-1 and HIV-2 infections and child survival in Abidjan, Cote d'Ivoire. BMJ 308 (1994) 441-443
29. Matheron S., Damond F., Benard A., Taieb A., and Campa P. CD4 recovery in treated HIV-2 infected adults is lower than expected: results from the France ANRS CO5 HIV-2 cohort. AIDS 20 (2006) 459-462
30. Drylewicz J., Matheron S., Lazaro E., Damond F., Bonnet F., Simon F., et al. Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS 22 (2008) 457-468
31. Witvrouw M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Antivir Chem Chemother 10 (1999) 211-217
32. Witvrouw M., Pannecouque C., Switzer W.M., Folks T.M., De Clercq E., and Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9 (2004) 57-65
33. Parkin N.T., and Schapiro J.M. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 9 (2004) 3-12
34. Smith N.A., Shaw T., Berry N., Vella C., Okorafor L., Taylor D., et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 42 (2001) 126-133
35. Adje-Toure C., Cheingsong R., Garcia-Lerma G., Eholie S., Borget M.Y., Bouchez J.M., et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17 Suppl 3 (2003) S49-54
36. Peeters M., Fransen K., Gershy-Damet G.M., Willems B., Koffi K., Coulibaly M., et al. Effect of methodology on detection of HIV-1/HIV-2 dual infection in Cote d'Ivoire. J Virol Methods 48 (1994) 23-30
37. Ampofo W.K., Koyanagi Y., Brandful J., Ishikawa K., and Yamamoto N. Seroreactivity clarification and viral load quantification in HIV-1 and HIV-2 infections in Ghana. J Med Dent Sci 46 (1999) 53-62
38. Rouet F., Ekouevi D.K., Inwoley A., Chaix M.-L., Burgard M., Bequet L., et al. Field evaluations of a rapid human immunodeficiency virus serial serological testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1). HIV-2 and dual HIV-1-HIV-2 infections in West African pregnant women. J Clin Microbiol 42 (2004) 4147-4153
39. Sagoe K., Mingle J., Affram R., Britton S., Dzokoto D., and Sonnerborg A. Virological characterization of dual HIV-1/HIV-2 seropositivity and infections in southern Ghana. Ghana Med J. 42 (2008) 16-21
40. George J.R., Ou C.-Y., Parekh B., Brattegaard K., Brown V., Boateng E., et al. Prevalence of HIV-1 and HIV-2 mixed infections in Cote d'Ivoire. Lancet 340 (1992) 337-339
41. Peeters M., Gershy-Damet G.-M., Fransen K., Koffi K., Coulibaly M., Delaporte E., et al. Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 340 (1992) 339-340